RxDoctor Payments DataLook up a doctor →

Drahmane Kaba, MD

Interventional Pain Medicine · Winter Park, FLNPI 1881838340

Payments from drug & device makers

$22,549in general payments, 2019–2025

Across 397 payments — averaging $56.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$5K
  • Boston Scientific$4K
  • Spinal Simplicity, LLC$4K
  • Vertiflex, Inc.$2K
  • Abbott$2K
  • Vertos Medical, Inc.$1K
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$8,35337%
  • Food & beverage$12,28554%
  • Education$1,7968%
  • Entertainment$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,549 in reported general payments places this provider in the 80th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$86,887
Medicare patients
111
Services billed
1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,046$62,342
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,274$54,738
Xtampza ErOxycodone Myristate63$29,863
Pregabalin553$19,098
MovantikNaloxegol Oxalate13$8,147
Tramadol Hcl937$8,133
Oxycodone Hcl429$7,219
Fentanyl61$7,202
Buprenorphine39$7,146
Oxymorphone Hcl ErOxymorphone Hcl12$5,921
Morphine Sulfate ErMorphine Sulfate303$5,839
Naloxone Hcl63$3,972
OxycontinOxycodone Hcl12$3,573
Acetaminophen-CodeineAcetaminophen With Codeine194$3,505
Morphine Sulfate127$3,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$388$29,86363 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$35$10,245166 claims
Redhill Biopharma Inc.Movantik$20$8,14713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →